Ga-68 DOTATATE PET/MRI for somatostatin-receptor brain tumors
Part of Brain & nervous system, Cancer, Hormones & metabolism clinical trials.
This trial tests how well a special scan (Ga-68 DOTATATE PET combined with MRI) helps diagnose and guide treatment for certain brain tumors that have somatostatin receptors. It may help doctors better find tumor recurrence or remaining tumor after treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a meningioma confirmed by pathology (tissue test) and concern for recurrence or leftover tumor on MRI
- Or you have another brain tumor known to have somatostatin receptor 2 (SSTR2) (the study may still enroll for feasibility)
- You can have MRI at your site—if you can’t do 3T, you may still do 1.5T MRI
- You can safely receive contrast dye used with MRI (gadolinium) and you have no known gadolinium contraindication
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special imaging agent called [Cu64]DOTATATE that helps surgeons see meningioma tumors during surgery. It may make tumor removal more complete and safer.
This study uses a special PET scan (DOTATATE) to help doctors plan radiation treatment for meningioma, a type of brain tumor. The scan may help target radiation more precisely, potentially improving outcomes.
This study tests an imaging scan using a special tracer (68Ga-HA-DOTATATE) to look for tumors that have somatostatin receptors. It may help doctors better locate suspected tumor sites so treatment planning can be more accurate.
This study tests how well a new PET/CT scan using 68Ga-DOTATATE can find neuroblastoma. It’s for children and young adults who are being planned for a different scan (123I-MIBG) to compare imaging results.
This trial tests a new type of PET scan using a radioactive tracer called 61Cu-NODAGA-LM3 to detect neuroendocrine tumors (NETs). The goal is to see if it works as well as or better than the standard scan. If you have a NET and need a scan for staging or treatment planning, you might be able to join.
This trial tests a new imaging method (68Ga-DOTA-mPNE PET/CT) to see if it can help detect cancers. It's for people who haven't had chemotherapy or radiation yet and will have a biopsy or surgery.
Hear when a new Meningioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.